Create a working network on all aspects of vaccines, from public health to special populations and vaccine impact.

Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials. 

Harboe ZB, Cordero E, Moran C, Kuijpers L, Epaulard O, Vollaard A. Lancet Infect Dis. 2025 Jul;25(7):e378-e379. 

Go to publication

Yellow fever in South America - A plea for action and call for prevention also in travelers from SLAMVI, ESGITM, EVASG, ALEIMC, GEPI-SEIMC, SEMEVI, and CMTZMV-ACIN. 

Rodriguez-Morales AJ, et al. Travel Med Infect Dis. 2025 Sep-Oct;67:102871. 

Go to publication

How can health care professionals address vaccine hesitancy in practice? 

Chemais M, MacDonald N, Dubé E, Søborg B, Cevik M, Harboe ZB, Velikov P; European Society of Clinical Microbiology and Infectious Diseases Vaccines Study Group. Clin Microbiol Infect. 2025 Aug 13:S1198-743X(25)00393-3. 

Go to publication

Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1). 

Beraud G, Bouetard L, Civljak R, Michon J, Tulek N, Lejeune S, Millot R, Garchet-Beaudron A, Lefebvre M, Veliko P, Festou B, Abgrall S, Lizatovic I K, Baldolli A, Esme H, Blanch S, Froidevaux G, Kapincheva N, Faucher JF, Duvnjak M, Afşar E, Švitek L, Yarimoglu S, Yarimoglu R, Janssen C, Epaulard O, on behalf of EVASG. Clin Microbiol Infect. 2023;29(5):642–650.

Go to publication

Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic. 

Bukan K, Pearce-Slade T, Eiberg M, Tinelli M, Yahav D, Tuells J, Epaulard O, Holler JG, Roed C, Søborg C, Jensen Stæhr JU, Barrella Harboe Z. Aging Clin Exp Res. 2023;35(5):917–923.

Go to publication

Measles in the 21st century: Is eradication possible and how? 

Post-graduate course

Go to courses